Loading
NASDAQHealthcareBiotechnology
Latest quote
$3.97
−$0.08 · -1.98%
Lexaria Bioscience Corp. is a biotechnology company focused on advanced drug delivery. Its proprietary and patented DehydraTECH technology is designed to significantly improve the oral delivery of active pharmaceutical ingredients, enhancing their absorption into the bloodstream. This innovative platform has shown impressive results, boosting the bioavailability of compounds such as cannabinoids and nicotine by 5 to 10 times, and in some cannabinoid applications, by as much as 27 times, when compared to standard formulations. DehydraTECH also drastically cuts the time of onset from hours to mere minutes and effectively neutralizes unpleasant tastes. Beyond its established uses, the technology is currently under evaluation for its potential application with orally administered antiviral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors, and various other compounds. A notable feature of DehydraTECH is its capacity to facilitate the passage of drugs across the blood-brain barrier. The company operates a licensed internal research facility and holds a substantial intellectual property portfolio, comprising 23 granted patents and roughly 50 pending patent applications globally. Founded in 2004, Lexaria Bioscience Corp. is headquartered in Kelowna, Canada.
Previous close
$3.97
−$0.08 · -1.98%
Regular session · ET · Market data may be delayed.
Lexaria Bioscience Corp. is a biotechnology company focused on advanced drug delivery. Its proprietary and patented DehydraTECH technology is designed to significantly improve the oral delivery of active pharmaceutical ingredients, enhancing their absorption into the bloodstream. This innovative platform has shown impressive results, boosting the bioavailability of compounds such as cannabinoids and nicotine by 5 to 10 times, and in some cannabinoid applications, by as much as 27 times, when compared to standard formulations. DehydraTECH also drastically cuts the time of onset from hours to mere minutes and effectively neutralizes unpleasant tastes. Beyond its established uses, the technology is currently under evaluation for its potential application with orally administered antiviral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors, and various other compounds. A notable feature of DehydraTECH is its capacity to facilitate the passage of drugs across the blood-brain barrier. The company operates a licensed internal research facility and holds a substantial intellectual property portfolio, comprising 23 granted patents and roughly 50 pending patent applications globally. Founded in 2004, Lexaria Bioscience Corp. is headquartered in Kelowna, Canada.
Day range
Current $3.97
52-week range
Current $3.97
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
57
Fair Value
Sentiment
44
Mixed
Risk
69
High Risk
Momentum
30
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Lexaria Bioscience Corp. is a biotechnology company focused on advanced drug delivery. Its proprietary and patented DehydraTECH technology is designed to significantly improve the oral delivery of active pharmaceutical ingredients, enhancing their absorption into the bloodstream. This innovative platform has shown impressive results, boosting the bioavailability of compounds such as cannabinoids and nicotine by 5 to 10 times, and in some cannabinoid applications, by as much as 27 times, when compared to standard formulations. DehydraTECH also drastically cuts the time of onset from hours to mere minutes and effectively neutralizes unpleasant tastes. Beyond its established uses, the technology is currently under evaluation for its potential application with orally administered antiviral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors, and various other compounds. A notable feature of DehydraTECH is its capacity to facilitate the passage of drugs across the blood-brain barrier. The company operates a licensed internal research facility and holds a substantial intellectual property portfolio, comprising 23 granted patents and roughly 50 pending patent applications globally. Founded in 2004, Lexaria Bioscience Corp. is headquartered in Kelowna, Canada.
Day range
Current $3.97
52-week range
Current $3.97
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 705.92K USD | 464.28K USD | 226.21K USD | 255.4K USD | 722.74K USD |
| Cost of goods sold | 2.72K USD | 4.82K USD | 31.5K USD | 71.84K USD | 175.35K USD |
| Gross profit | 703.2K USD | 459.46K USD | 194.71K USD | 183.56K USD | 547.39K USD |
| Research and development | 8.24M USD | 2.36M USD | 3.67M USD | 1.84M USD | 1.26M USD |
| Selling, general, and administrative | 4.35M USD | 3.85M USD | 3.06M USD | 4.96M USD | 4.97M USD |
| Operating expenses | 12.58M USD | 6.21M USD | 6.73M USD | 6.8M USD | 6.23M USD |
| Interest income | 3.02K USD | 14.31K USD | 43.19K USD | — | — |
| Depreciation and amortization | 87.83K USD | 76.15K USD | 145.4K USD | 102.72K USD | 147.6K USD |
| Operating income | −11.88M USD | −5.75M USD | −6.53M USD | −6.62M USD | −5.69M USD |
| Net income | −11.9M USD | −5.8M USD | −6.66M USD | −7.27M USD | −4.03M USD |
Company facts updated Sep 13, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$1.50
62.22% downside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Aug 3, 2026 | 1:15 | — | — |
Stock split | Jan 12, 2021 | 1:30 | — | — |
Stock split | Dec 16, 2015 | 11:10 | — | — |
Stock split | Jun 30, 2009 | 1:4 | — | — |
Effective Aug 3, 2026
1:15
Effective Jan 12, 2021
1:30
Effective Dec 16, 2015
11:10
Effective Jun 30, 2009
1:4
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
